| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
This study assessed the pharmacokinetic profiles of administering tegaserod (HTF 919) at different time intervals with respect to a meal. It was a randomized, open-label, two-phase, five-period crossover study. In the first phase, 18 healthy subjects received a single 12 mg oral dose of tegaserod administered either 30 or 15 minutes prior to the start of the 600-calorie, fat-rich breakfast. In the second phase, subjects received a single 12 mg oral dose of tegaserod 1 minute before, 2.5 hours after the start of meal, or with a continued 4-hour postdose fast. Safety assessment and plasma samples for the determination of drug concentration were obtained for 24 hours postdose. Noncompartmental analysis results indicated that the AUC of tegaserod was reduced by almost half under fed conditions compared to the fasted condition. Exploratory analyses were implemented to further investigate the absorption characteristics of tegaserod under different fed conditions. A numerical deconvolution approach was used to obtain the tegaserod oral absorption versus time profiles under both fasted and fed conditions. The tegaserod oral absorption versus time profiles were then fitted by NONMEM to a model containing two absorption phases. Based on the absorption analyses, we found that the reduction in the bioavailability of tegaserod under fed conditions was primarily due to a decrease in the extent of absorption and less so to a decrease in the absorption rate(s). Therefore, although the timing of administration of food does not appear to significantly alter the pharmacokinetics of tegaserod, the administration of food reduces the AUC by approximately 50%.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Dai, M. Pfister, A. Blackwood-Chirchir, and A. Roy Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia J. Clin. Pharmacol., November 1, 2008; 48(11): 1254 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhou, H. Jang, R. M. Fleischmann, E. Bouman-Thio, Z. Xu, J. C. Marini, C. Pendley, Q. Jiao, G. Shankar, S. J. Marciniak, et al. Pharmacokinetics and Safety of Golimumab, a Fully Human Anti-TNF-{alpha} Monoclonal Antibody, in Subjects With Rheumatoid Arthritis J. Clin. Pharmacol., March 1, 2007; 47(3): 383 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Swan, H. Zhou, A. Horowitz, L. Alladina, M. Hubert, S. Appel-Dingemanse, S. Osborne, L. Lambrecht, and J. F. McLeod Tegaserod Pharmacokinetics Are Similar in Patients with Severe Renal Insufficiency and in Healthy Subjects J. Clin. Pharmacol., April 1, 2003; 43(4): 359 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhou Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles J. Clin. Pharmacol., March 1, 2003; 43(3): 211 - 227. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
